{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:15:24Z","timestamp":1775229324840,"version":"3.50.1"},"reference-count":22,"publisher":"Central Research Institute for Epidemiology","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["virusjour.crie.ru"],"crossmark-restriction":false},"short-container-title":["Problems of Virology"],"abstract":"<jats:p>Introduction. Epstein\u2013Barr virus (EBV) is a widespread gamma-herpesvirus associated with a number of malignancies, including nasopharyngeal carcinoma and gastric cancer (GC\/EBV+). The primary oncogenic protein of EBV is latent membrane protein 1 (LMP1). Genetic variability of the LMP1 protein affects its oncogenic activity and clinical manifestations.\r\nObjective. To investigate the optimal threshold value for EBV viral load, determine the correlation between high viral load and the detection of the LMP1 gene in the blood of patients with GC\/EBV+, and to identify mutations in the C-terminal domains of the LMP1 gene that may affect protein function.\r\nMaterials and methods. Total DNA was extracted from 227 blood samples of GC patients. The LMP1 gene was amplified using nested PCR. EBV DNA viral load in blood samples was analyzed by qPCR, followed by receiver operating characteristic (ROC) analysis and interquartile range (IQR) assessment. A selection criterion for positive DNA samples (EBV+) was established based on the mean viral load and ROC threshold.\r\nResults. ROC curve analysis and descriptive statistics identified 23 EBV-positive (EBV+) DNA samples, with the following results: AUC (area under the curve) = 0.83, optimal threshold 526.92 copies\/reaction, sensitivity 0.69, specificity 0.87, and mean viral load: 513.5 copies\/reaction. A statistically significant association was found between detection of the LMP1 gene in the blood and viral load level (\u03c72 test p = 0.018; Mann\u2013Whitney U test p  0.0001). Additionally, synonymous and nonsynonymous mutations were identified in regions of LMP1 gene coding the C-terminal activating domains (CTAR1 and CTAR2).\r\nConclusion. The findings highlight the heterogeneous molecular nature of EBV-associated gastric cancer, including genetic mutations in the LMP1 gene.<\/jats:p>","DOI":"10.36233\/0507-4088-359","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:24:39Z","timestamp":1774286679000},"page":"62-72","update-policy":"https:\/\/doi.org\/10.36233\/0372-9311-crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Polymorphisms in the &lt;i&gt;LMP1&lt;\/i&gt; gene in patients with gastric cancer associated with Epstein\u2013Barr virus (&lt;i&gt;Orthoherpesviridae: Gammaherpesvirinae: Lymphocryptovirus: Lymphocryptovirus humangamma 4&lt;\/i&gt;)"],"prefix":"10.36233","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0249-4574","authenticated-orcid":false,"given":"Alexandra S.","family":"Vasilyeva","sequence":"additional","affiliation":[{"name":"N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia"},{"name":"I.I. Mechnikov Research Institute of Vaccines and Serums"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2397-0304","authenticated-orcid":false,"given":"Alina A.","family":"Margusheva","sequence":"additional","affiliation":[{"name":"N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-2285","authenticated-orcid":false,"given":"Artem D.","family":"Molchanov","sequence":"additional","affiliation":[{"name":"N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia"},{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4212-5093","authenticated-orcid":false,"given":"Artem A.","family":"Rtishchev","sequence":"additional","affiliation":[{"name":"I.I. Mechnikov Research Institute of Vaccines and Serums"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-6263","authenticated-orcid":false,"given":"Bogdan S.","family":"Cherepovich","sequence":"additional","affiliation":[{"name":"I.I. Mechnikov Research Institute of Vaccines and Serums"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4657-382X","authenticated-orcid":false,"given":"Valeria A.","family":"Domanskaya","sequence":"additional","affiliation":[{"name":"N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia"},{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-4364","authenticated-orcid":false,"given":"Vladimir E.","family":"Gurtsevich","sequence":"additional","affiliation":[{"name":"N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6209-977X","authenticated-orcid":false,"given":"Ksenia V.","family":"Smirnova","sequence":"additional","affiliation":[{"name":"N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22004","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Chen M.R. Epstein-Barr virus, the immune system, and associated diseases. Front. Microbiol. 2011; 2: 5. https:\/\/doi.org\/10.3389\/fmicb.2011.00005","DOI":"10.3389\/fmicb.2011.00005"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens \u2013 Part B: biological agents. Lancet Oncol. 2009; 10(4): 321\u20132. https:\/\/doi.org\/10.1016\/s1470-2045(09)70096-8","DOI":"10.1016\/S1470-2045(09)70096-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Damania B., Kenney S.C., Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022; 185(20): 3652\u201370. https:\/\/doi.org\/10.1016\/J.CELL.2022.08.026","DOI":"10.1016\/j.cell.2022.08.026"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer. 2004; 4(10): 757\u201368. https:\/\/doi.org\/10.1038\/NRC1452","DOI":"10.1038\/nrc1452"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wang L., Ning S. New look of EBV LMP1 signaling landscape. Cancers (Basel). 2021; 13(21): 5451. https:\/\/doi.org\/10.3390\/cancers13215451","DOI":"10.3390\/cancers13215451"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Chen J., Hu C.F., Hou J.H., Shao Q., Yan L.X., Zhu X.F., et al. Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J. Transl. Med. 2010; 8: 30. https:\/\/doi.org\/10.1186\/1479-5876-8-30","DOI":"10.1186\/1479-5876-8-30"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Miller W.E., Edwards R.H., Walling D.M., Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J. Gen. Virol. 1994; 75(Pt. 10): 2729\u201340. https:\/\/doi.org\/10.1099\/0022-1317-75-10-2729","DOI":"10.1099\/0022-1317-75-10-2729"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N., Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology. 1999; 261(1): 79\u201395. https:\/\/doi.org\/10.1006\/viro.1999.9855","DOI":"10.1006\/viro.1999.9855"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Mainou B.A., Raab-Traub N. LMP1 strain variants: biological and molecular properties. J. Virol. 2006; 80(13): 6458\u201368. https:\/\/doi.org\/10.1128\/JVI.00135-06","DOI":"10.1128\/JVI.00135-06"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Gantuz M., Lorenzetti M.A., Chabay P.A., Preciado M.V. A novel recombinant variant of latent membrane protein 1 from Epstein Barr virus in Argentina denotes phylogeographical association. PLoS One. 2017; 12(3): e0174221. https:\/\/doi.org\/10.1371\/journal.pone.0174221","DOI":"10.1371\/journal.pone.0174221"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Gurtsevitch V.E., Senyuta N.B., Ignatova A.V., Lomaya M.V., Kondratova V.N., Pavlovskaya A.I., et al. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions. J. Gen. Virol. 2017; 98(8): 2118\u201327. https:\/\/doi.org\/10.1099\/jgv.0.000889","DOI":"10.1099\/jgv.0.000889"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Shao J.Y., Li Y.H., Gao H.Y., Wu Q.L., Cui N.J., Zhang L., et al., Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer. 2004; 100(6): 1162\u201370. https:\/\/doi.org\/10.1002\/CNCR.20099","DOI":"10.1002\/cncr.20099"},{"key":"ref13","unstructured":"Lo Y.M., Chan L.Y., Chan A.T., Leung S.F., Lo K.W., Zhang J., et al., Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999; 59(21): 5452\u20135."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Smirnova K.V., Senyuta N.B., Botezatu I.V., Dushenkina T.E., Lubenskaya A.K., Frolovskaya A.A., et al., Epstein\u2013Barr virus in the ethnic Tatars population: the infection and sequence variants of LMP1 oncogene. Uspekhi molekulyarnoi onkologii. 2018; 5(3): 65\u201374. https:\/\/doi.org\/10.17650\/2313-805X-2018-5-3-65-74 https:\/\/elibrary.ru\/vloxpu (in Russian)","DOI":"10.17650\/2313-805X-2018-5-3-65-74"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology. 1999; 261(1): 79\u201395. https:\/\/doi.org\/10.1006\/viro.1999.9855","DOI":"10.1006\/viro.1999.9855"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Luo B., Wang Y., Wang X.F., Liang H., Yan L.P., Huang B.H., et al. Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J. Gastroenterol. 2005; 11(5): 629\u201333. https:\/\/doi.org\/10.3748\/wjg.v11.i5.629","DOI":"10.3748\/wjg.v11.i5.629"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Sharma Y., Miladi M., Dukare S., Boulay K., Caudron-Herger M., Gro\u00df M., et al. A pan-cancer analysis of synonymous mutations. Nat. Commun. 2019; 10(1): 2569. https:\/\/doi.org\/10.1038\/s41467-019-10489-2","DOI":"10.1038\/s41467-019-10489-2"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Higuchi M., Izumi K.M., Kieff E. Epstein\u2013Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: Protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc. Natl Acad. Sci. USA. 2001; 98(8): 4675\u201380. https:\/\/doi.org\/10.1073\/pnas.081075298","DOI":"10.1073\/pnas.081075298"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Dawson C.W., Tramountanis G., Eliopoulos A.G., Young L.S. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase\/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biol. Chem. 2003; 278(6): 3694\u2013704. https:\/\/doi.org\/10.1074\/jbc.m209840200","DOI":"10.1074\/jbc.M209840200"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Mainou B.A., Everly D.N. Jr., Raab-Traub N. Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene. 2005; 24(46): 6917\u201324. https:\/\/doi.org\/10.1038\/sj.onc.1208846","DOI":"10.1038\/sj.onc.1208846"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Izumi K.M., Kieff E.D. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc. Natl Acad. Sci. USA. 1997; 94(23): 12592\u20137. https:\/\/doi.org\/10.1073\/PNAS.94.23.12592","DOI":"10.1073\/pnas.94.23.12592"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mainou B.A., Everly D.N., Raab-Traub N. Unique signaling properties of CTAR1 in LMP1-mediated transformation. J. Virol. 2007; 81(18): 9680\u201392. https:\/\/doi.org\/10.1128\/jvi.01001-07","DOI":"10.1128\/JVI.01001-07"}],"container-title":["Problems of Virology"],"original-title":[],"link":[{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/16826\/1079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/16826\/1079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:36:42Z","timestamp":1775227002000},"score":1,"resource":{"primary":{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/view\/16826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,23]]}},"URL":"https:\/\/doi.org\/10.36233\/0507-4088-359","relation":{},"ISSN":["2411-2097","0507-4088"],"issn-type":[{"value":"2411-2097","type":"electronic"},{"value":"0507-4088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}